BACKGROUND: It is not clear whether the progressive changes in brain microstructural deficits documented in previous longitudinal magnetic resonance imaging (MRI) studies might be due to the disease process or to other factors such as medication. It is important to explore the longitudinal alterations in white-matter (WM) microstructure in antipsychotic-naive patients with first-episode schizophrenia during the very early phase of treatment when relatively 'free' from chronicity. METHOD: Thirty-five patients with first-episode schizophrenia and 22 healthy volunteers were recruited. High-resolution diffusion tensor imaging (DTI) was obtained from participants at baseline and after 6 weeks of treatment. A 'difference map' for each individual was calculated from the 6-week follow-up fractional anisotropy (FA) of DTI minus the baseline FA. Differences in Positive and Negative Syndrome Scale (PANSS) scores and Global Assessment of Functioning (GAF) scores between baseline and 6 weeks were also evaluated and expressed as a 6-week/baseline ratio. RESULTS: Compared to healthy controls, there was a significant decrease in absolute FA of WM around the bilateral anterior cingulate gyrus and the right anterior corona radiata of the frontal lobe in first-episode drug-naive patients with schizophrenia following 6 weeks of treatment. Clinical symptoms improved during this period but the change in FA did not correlate with the changes in clinical symptoms or the dose of antipsychotic medication. CONCLUSIONS: During the early phase of treatment, there is an acute reduction in WM FA that may be due to the effects of antipsychotic medications. However, it is not possible to entirely exclude the effects of underlying progression of illness.
BACKGROUND: It is not clear whether the progressive changes in brain microstructural deficits documented in previous longitudinal magnetic resonance imaging (MRI) studies might be due to the disease process or to other factors such as medication. It is important to explore the longitudinal alterations in white-matter (WM) microstructure in antipsychotic-naive patients with first-episode schizophrenia during the very early phase of treatment when relatively 'free' from chronicity. METHOD: Thirty-five patients with first-episode schizophrenia and 22 healthy volunteers were recruited. High-resolution diffusion tensor imaging (DTI) was obtained from participants at baseline and after 6 weeks of treatment. A 'difference map' for each individual was calculated from the 6-week follow-up fractional anisotropy (FA) of DTI minus the baseline FA. Differences in Positive and Negative Syndrome Scale (PANSS) scores and Global Assessment of Functioning (GAF) scores between baseline and 6 weeks were also evaluated and expressed as a 6-week/baseline ratio. RESULTS: Compared to healthy controls, there was a significant decrease in absolute FA of WM around the bilateral anterior cingulate gyrus and the right anterior corona radiata of the frontal lobe in first-episode drug-naive patients with schizophrenia following 6 weeks of treatment. Clinical symptoms improved during this period but the change in FA did not correlate with the changes in clinical symptoms or the dose of antipsychotic medication. CONCLUSIONS: During the early phase of treatment, there is an acute reduction in WM FA that may be due to the effects of antipsychotic medications. However, it is not possible to entirely exclude the effects of underlying progression of illness.
Authors: Arvind Caprihan; Thomas Jones; Hongji Chen; Nicholas Lemke; Christopher Abbott; Clifford Qualls; Jose Canive; Charles Gasparovic; Juan R Bustillo Journal: Neuropsychopharmacology Date: 2015-03-18 Impact factor: 7.853
Authors: Patricia Alvarado-Alanis; Pablo León-Ortiz; Francisco Reyes-Madrigal; Rafael Favila; Oscar Rodríguez-Mayoral; Humberto Nicolini; Mariana Azcárraga; Ariel Graff-Guerrero; Laura M Rowland; Camilo de la Fuente-Sandoval Journal: Schizophr Res Date: 2015-01-22 Impact factor: 4.939
Authors: Nina Vanessa Kraguljac; David Matthew White; Nathan Hadley; Jennifer Ann Hadley; Lawrence Ver Hoef; Ebony Davis; Adrienne Carol Lahti Journal: Schizophr Bull Date: 2016-02-12 Impact factor: 9.306
Authors: Konasale M Prasad; Catherine H Upton; Claudiu S Schirda; Vishwajit L Nimgaonkar; Matcheri S Keshavan Journal: Schizophr Res Date: 2014-10-30 Impact factor: 4.939
Authors: Paul Klauser; Simon T Baker; Vanessa L Cropley; Chad Bousman; Alex Fornito; Luca Cocchi; Janice M Fullerton; Paul Rasser; Ulrich Schall; Frans Henskens; Patricia T Michie; Carmel Loughland; Stanley V Catts; Bryan Mowry; Thomas W Weickert; Cynthia Shannon Weickert; Vaughan Carr; Rhoshel Lenroot; Christos Pantelis; Andrew Zalesky Journal: Schizophr Bull Date: 2017-03-01 Impact factor: 9.306
Authors: Philip R Szeszko; Delbert G Robinson; Toshikazu Ikuta; Bart D Peters; Juan A Gallego; John Kane; Anil K Malhotra Journal: Neuropsychopharmacology Date: 2013-10-16 Impact factor: 7.853